Nasdaq rxrx.

Nov 10, 2023 · With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) may be sending very bearish signals at the moment, given that almost half of all the Biotechs ... Oct 11, 2023 · The company has grabbed plenty of headlines recently. It has been a tumultuous year for the clinical-stage biotech Recursion Pharmaceuticals ( RXRX -0.80%). Earlier this year, the company's shares ... Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» …December 9, 2023 at 11:06 AM · 4 min read. In a notable insider transaction, CEO Christopher Gibson sold 59,829 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) on December 6, 2023. This ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages ...It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ...

Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing. Get the latest ...Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.For a biotech like Recursion Pharmaceuticals (RXRX-1.25%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...4. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best and most notable AI healthcare stocks to buy. The Utah-based Recursion ...Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities).

With a relentless focus on transforming the biotechnology landscape through its artificial intelligence (AI) and machine learning (ML) driven platform, Recursion Pharmaceuticals (NASDAQ:RXRX ...

Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing ...

See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... Ignatiev. At a Glance. Recursion Pharmaceuticals (NASDAQ:RXRX) is carving out a vanguard role in TechBio by synergizing wet-lab biology with advanced computational tools.The firm's Q2 earnings ...SALT LAKE CITY , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16,RXRX Latest Real Time Trades ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, and more asset classes. /Nov 10, 2023 · With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) may be sending very bearish signals at the moment, given that almost half of all the Biotechs ... Recursion Pharmaceuticals (NASDAQ: RXRX) leverages AI and machine learning to revolutionize the discovery of drug candidates. They analyze vast amounts of biological and imaging data from assays, ...

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ...SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Oct 14, 2021 · The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ... Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...

Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Recursion Pharmaceuticals (NASDAQ:RXRX) is one of the high-flying stocks gaining focus in today’s market. Indeed, shares of RXRX stock are rocketing more than 10% higher today on some rather ...

Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors …Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 320.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission.The institutional investor owned 3,523,124 shares of the company's stock …Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. NASDAQ: RXRX saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) leader Nvidia Co. Nasdaq: NVDA.The news generated volume not seen in years, bringing the spotlight onto the AI-powered drug discovery that …December 15, 2023 at 3:06 AM · 4 min read. In a notable insider transaction, CFO Michael Secora of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 50,000 shares of the company's stock on ...Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing ... With a relentless focus on transforming the biotechnology landscape through its artificial intelligence (AI) and machine learning (ML) driven platform, Recursion Pharmaceuticals (NASDAQ:RXRX ...Institutional investors have sold a total of 19,621,281 shares in the last 24 months. This volume of shares sold represents approximately $160.50M in transactions. Related Companies: ImmunityBio Institutional Ownership. Neumora Therapeutics Institutional Ownership. This page (NASDAQ:RXRX) was last updated on 1/15/2024 …Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities).

Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ...

The idea of Recursion Pharmaceuticals (RXRX-4.65%) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify ...

That's what's happening with Recursion Pharmaceuticals ( RXRX -4.40%), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery ...Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...Jan 19, 2024 · Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ... Nasdaq GS (USD) As of 12: ... Feb 17, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ... iLexx. Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week.This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and ...5 days ago · RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Jan 26, 2024 4:03 p.m. EST Delayed quote $ 9.87 0.09 0.92% After Hours... AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ...So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of .../PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery,...

RXRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Recursion Pharmaceuticals, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and …On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...Recursion Pharmaceuticals Stock Down 2.6 %. Shares of NASDAQ RXRX opened at $9.63 on Monday. The business has a 50-day simple moving average of $8.96 and a two-hundred day simple moving average of ...Instagram:https://instagram. corolla xrs for sale.szkola i edukacjacrispr cas applied to tgf beta induced emt labster quizletpersonalizestore AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... take me to lowepercent27s home improvementdave and busters bakersfield photos An analysis of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock in terms of its daily trading volume indicates that the 3-month average is 4.10 million. However, this figure increases on the past 10-day timeline to an average of 4.76 million. Current records show that the company has 183.21M in outstanding shares. i have a master Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Stock. Equities. Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ): Stock quote, stock chart, quotes, analysis, …Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.